Company to Report Interim Celgosivir 4-Week Viral Kinetics Study Data on
Monday December 3, 2007
VANCOUVER and SAN DIEGO, Nov. 30 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious diseases, will host
a conference call and webcast on Thursday, December 13, 2007 at 11:00 a.m. ET
(8:00 a.m. PT) to discuss financial results for the second fiscal quarter
ended October 31, 2007 and provide an update on company activities. To
participate in the conference call, please dial 416-644-3418 or
1-800-732-1073. The call will be available for replay until December 27, 2007
by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21255722
(followed by the number sign). The live and archived webcast can be accessed
through the company's website at www.migenix.com for the next 90 days.
Additionally, the Company will report interim 4-week data from a Phase II
viral kinetics combination study of celgosivir in patients with chronic HCV
(genotype 1) infection on Monday December 3, 2007.
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.
James M. DeMesa, M.D.
President & CEO
For further information:
For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, email@example.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com